drugset / Trial / NCT07091279
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
Phase 2
Recruiting
60 enrolled
Jeremy Veenstra-vanderweele
New York State Institute for Basic Research · collabUnited States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to learn if propranolol can help reduce challenging behaviors associated with Autism Spectrum Disorder, including aggression, self-injury, and severe disruptive behaviors. Participants will be randomly assigned to receive either propranolol or a placebo (a look-alike substance that contains no drug) daily for 12 weeks. After the 12 weeks, all participants will have the opportunity to receive propranolol for an additional 12 weeks.
Timeline
- Start
- 2026-01-30
- Primary completion
- 2028-11
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Propranolol | Small molecule | 200 mg | Oral |